Table 2 Study design and setting overview
Study | Country | Costing year | Patients | Compared interventions | Type of economic evaluation | Model type | Perspective | Time horizon | WTP threshold ($2022) | Discount rate | Sensitivity analyses | Document Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Soo Kun Lim 2023 [17] | Malaysia | 2022 | CKD with or without T2DM | dapagliflozin as an add-on to standard of care (SoC) vs. SoC | CEA | Markov model | Healthcare system perspective | Life-time | $11,111/QALY | 3% | OWSA and PSA | Article |
Bao-Ngoc Nguyen 2023 [18] | Canada | 2021 | CKD and type 2 diabetes (T2D) | dapagliflozin plus standard of care (SoC) vs. SoC alone | CEA | Markov model | Healthcare system perspective | Life-time | C$50 000/ QALY ($44404.88/QALY) | 1.5% | scenario analyses and OWSA | Article |
Phil McEwan 2022 [20] | UK, Germany, and Spain | 2021 | CKD | dapagliflozin plus standard therapy vs. standard therapy | CEA | Markov model | payer perspective | Life-time | $27,510/QALY ($29437.17/QALY) (UK); $35,503/QALY ($ 37990.11/QALY) (Germany and Spain) | 3.5% (UK); 3.0% (Germany and Spain) | Scenario Analyses, OWSA, and PSA | Article |
Satoshi Kodera 2022 [21] | Japan | N | CKD stages 3a and 3b that was not limited to diabetic nephropathy | with and without dapagliflozin | CEA | Markov model | Healthcare system perspective | 20 years | 5 million Japanese yen (JPY)/QALY ($ 53671.10/QALY) | 2% | Scenario Analyses, OWSA, and PSA | Article |
Rebecca L. Tisdale 2022 [22] | USA | 2019 | Non-diabetic CKD | Dapagliflozin plus standard care versus standard care only | CEA | Markov model | Healthcare system perspective | Life-time | $100,000/QALY ($ 113271.25/QALY) | 3% | Scenario Analyses, OWSA, and PSA | Article |
Kriengsak Vareesangthip 2022 [23] | Thailand | 2020 | CKD | dapagliflozin in addition to standard of care (SoC) compared with SoC alone | CUA | Markov model | a societal perspective | lifetime horizon | $5168.96 /QALY ($ 5779.51/QALY) | 3% | Scenario Analyses, OWSA, and PSA | Article |
zhong ling 2024 [24] | China | N | CKD with or without T2DM | Dapagliflozin plus standard care versus standard care only | CUA | Markov model | payer perspective | Life-time | 242,928 CNY/QALY ($ 68466.33/QALY) | 3% | OWSA | Article |
Phil McEwan 2024 [28] | UK, Spain, Italy, and Japan | 2022 | CKD with or without T2DM | Dapagliflozin plus standard care versus standard care only | CEA | Markov model | Healthcare system perspective | lifetime horizon | $28,777/QALY (UK), $39,063/QALY (Spain), $35,261/QALY (Italy), and $53,671/QALY (Japan) | 3.5% in UK, 3% in Spain and Italy and 2% in Japan | Scenario Analyses, OWSA, and PSA | Article |
Buritica, M. P. 2022 [16] | Mexico | N | CKD | dapagliflozin as add on to standard therapy vs. standard therapy | CEA | Markov model | Healthcare system perspective | 15 years | N | 5% | PSA | Conference Abstract |
Nava-Vargas 2023 [1] | Mexico | N | DKD | dapagliflozin and standard therapy vs. standard therapy | CEA | Markov model | N | Life-time (100 years old) | N | N | N | Conference Abstract |
Phil McEwan 2021 [19] | UK | N | CKD | dapagliflozin plus standard therapy vs. standard therapy | CEA | Markov model | The payer perspective | Life-time | £20,000/QALY ($30333.83/QALY) | 3.5% | N | Conference Abstract |
Ordoñez J 2022a [25] | Costa Rica | N | CKD with or without T2DM | dapagliflozin or no treatment | CUA | Markov model | the third payer perspective | 12, 24, and 32 months | $36,230/QALY | N | PSA | Conference Abstract |
Ordoñez J 2022b [26] | Dominican Republic | N | CKD with or without T2DM | dapagliflozin or no treatment | CUA | Markov model | the third payer perspective | 12, 24, and 32 months | $21,805/QALY | N | PSA | Conference Abstract |
Ordoñez J 2022c [27] | Panama | N | CKD with or without T2DM | dapagliflozin or no treatment | CUA | Markov model | the third payer perspective | 12, 24, and 32 months | $36,807/QALY | N | PSA | Conference Abstract |